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A B S T R A C T
KSHV-associated inflammatory cytokine syndrome (KICS) is caused by Kaposi's sarcoma-associated herpesvirus
(KSHV). KICS is associated with high-level, systemic replication of KSHV. This study characterized the clinical
and virologic features of a KICS patient over time. Additionally, it compared the cytokine profiles of the KICS
case to Kaposi's sarcoma (KS) (n=11) and non-KS (n=6) cases. This KICS case presented with elevated levels
of KSHV and IL-10, as expected. Surprisingly, this case did not have elevated levels of IL-6 or human im-
munodeficiency virus 1 (HIV-1). Nevertheless, treatment with anti-IL6 receptor antibody (tocilizumab) reduced
KSHV viral load and IL-10. The KSHV genome sequence showed no significant changes over time, except in
ORF24. Phylogenetic analysis established this isolate as belonging to KSHV clade A and closely related to other
US isolates. These findings suggest IL-10 as potential biomarker and therapy target for KICS.
1. Introduction
Kaposi's Sarcoma associated herpesvirus (KSHV), also known as
human herpesvirus-8 (HHV8), is the etiologic agent of Kaposi's sarcoma
(KS), primary effusion lymphoma (PEL), and the plasmablastic variant
of multicentric Castleman disease (KSHV-MCD) (reviewed in (Dittmer
and Damania, 2016)). Primary KSHV infections are largely asympto-
matic. KSHV-associated malignancies and KSHV reactivation are asso-
ciated with immune suppression of multiple etiologies, including those
that are caused by human immunodeficiency virus (HIV). KS is the
single most common cancer in people living with HIV today. KS has a
unique clinical manifestation of violaceous lesions in the skin, the re-
spiratory system, and gastrointestinal tract. Interestingly, pediatric KS
in a KSHV-endemic region often presents as lymphadenopathy without
any skin lesions (El-Mallawany et al., 2019). PEL and KSHV-MCD are B-
cell lymphoproliferative disorders caused by KSHV. In KS and PEL,
KSHV establishes a latent infection. In KSHV-MCD, KSHV undergoes
viral lytic reactivation in a large proportion of KSHV-infected cells. In
these three diseases, systemic KSHV viral loads seldom exceed 104 co-
pies/ml (Tamburro et al., 2012). By contrast, KSHV-associated in-
flammatory cytokine syndrome (KICS) is a clinically-defined disease of
KSHV that is associated with very high levels of KSHV in the blood
(Polizzotto et al., 2016; Uldrick et al., 2010). KSHV-MCD, KICS and
KSHV immune reconstitution syndrome (KS-IRIS) or KS flares share
overlapping clinical features, such as lymphadenopathy, cytopenia, and
inflammatory symptoms. The symptoms are thought to be secondary to
systemically elevated levels of human interleukin 6 and/or viral inter-
leukin 6 secondary to KSHV replication (reviewed in (Oksenhendler
et al., 2019; Yu et al., 2017)). Of note, KICS can develop despite control
of HIV viremia (Cantos et al., 2017). Thus, KICS is not simply a mani-
festation of acquired immune deficiency syndrome (AIDS), rather HIV
replication and KSHV replication are at times uncoupled.
As KICS and KSHV-MCD share a similar clinical representation,
KSHV-MCD must be ruled out by pathologic evaluation before KICS can
be diagnosed. Currently, KICS has no established treatment. Treatment
strategies similar to KSHV-MCD have been suggested, such as rituximab
and liposomal doxorubicin, or high-dose zidovudine and valganciclovir
(Lurain et al., 2018; Prieto-Barrios et al., 2018; Uldrick et al., 2011,
2014). Anti-IL6R antibodies such as tocilizumab or anti-IL6 antibodies
such as siltuximab have been sporadically explored in MCD, as this
treatment has become the standard of care for non-virally associated,
idiopathic Castleman's disease (van Rhee et al., 2018). Anti-IL6R
therapy has not been tested in KICS.
This report describes a KICS patient treated with anti-IL6R
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2. Methods
Plasma isolation. 20mL of whole blood was collected in purple cap
EDTA tubes. Samples were centrifuged two times at 400 g for 10min.
Plasma was stored in 1mL aliquots in matrix tubes (Matrix
Technologies Corp. #4252) at -80 °C.
DNA extraction. DNA was extracted using a Roche MagNA Pure
Compact Instrument (Roche, #03731146001) and Nucleic Acid
Isolation Kit I -Large Volume (Roche, #03730972001). 10 μL of a
control plasmid, Fly 2.0 (Addgene #117418), was added to each sample
to serve as control for DNA extraction efficiency.
Viral load assay. Following DNA extraction qPCR was performed
on the samples using a 3-primer master mix assay. Primers were de-
signed for KSHV, EBV, and FLY 2.0 and obtained from Europhins
Genomics. KSHV: LANA78-F GGAAGAGCCCATAATCTTGC and
LANA78(2)-R GCCTCATACGAACTCCAGGT. EBV (Hilscher et al.,
2005): EBNA3C-F AAGGTGCATTTACCCCACTG and EBNA3C-R AGCA
GTAGCTTGGGAACACC. Fly: Flyflap-f AATCATAAAGCGTTTTAAGCTC
CAACGA and Fly Flyflap-r AATCATAATTCCTGACTCCCAAGTGGAC.
Individual master mixes were made by adding 20 μL of 5 μM of primer
pair to 400 μL of SYBR® Select Master Mix (ThermoFisher/ABI
#4472920). 9 μL of DNA sample and 9.9 μl of master mix were used for
each well (125 nM final concentration). For each primer pair, we gen-
erated an oligonucleotide to serve as a template for creating a copy
number standard curve. The oligonucleotide standards (Eurofin Geno-
mics) were diluted to construct standard curves with a starting con-
centration of 100,000 copies/μL. Reactions were set up using a Freedom
Evo 150 robot (Tecan Group Ltd.) in LightCycler® 480 Multiwell 384
Plates (Roche Catalog # 04729749001). PCR reactions were carried out
and read with a LightCycler® 480 II/384 (Roche) instrument. Cycle
conditions were 95 °C: 5min, (95 °C: 15 s, 62 °C: 1min, x40).
ELISA. IL-6, IL-8 and IL-10 were quantify using ready-set-go kit
(eBioscience) per manufacturer instructions. Plates were washed with
plate washer ELx405 (Biotek). Absorbance was measured at 450 nm
using spectrophotometer Infinite M200 PRO (Tecan). For DNAse
treatment 100 μL of 10x RQ1 buffer (Promega Inc). and 400 μl of water
was added to 500 μL of serum. Each sample was treated using 2.5 μL
DNAse 1 U/μl and incubated at 37 °C for 30min. Afterwards, 6 μL of
EGTA Stop Buffer was added to the samples and incubated at 65 °C for
10min prior to automated DNA extraction as describe above.
Luminex assay and analysis. Plasma was tested with a human
cytokine magnetic 35-plex panel (Life Technologies) per the manufac-
turer's instructions and analyzed with a MAGPIX instrument (Luminex).
R version 3.5.1 was used to conduct analysis and generate figures. Data
was scaled and subjected to principle component analysis (PCA) The
code is available at: https://bitbucket.org/dittmerlab/r_methods_
cytokine/src/master/and the original data are in Supplemental Table 1.
Viral sequencing and mutation calling. Total nucleic acid was
extracted from 1mL of plasma as described above and quantitated by
Qubit 3.0 dsDNA HS Assay (Life Technologies). Custom Ion Ampliseq
primer pools (Life Technologies) were designed to amplify the viral
genome using KSHV BAC16 (JSC-1 isolate, GQ994935) as the target.
Libraries were prepared from 100 ng total DNA with Ion AmpliSeq
Exome RDY Library Preparation Kit (Life Technologies) using protocol
MAN00009808 Rev: A.0. Libraries were quantitated by Qubit dsDNA
HS Assay, sized with Agilent Bioanalyzer 2100 High Sensitivity DNA
Assay (Agilent Technologies), and pooled to 80 pM final concentration.
Templating and loading onto the Ion 540 Chip (Life Technologies) were
automated on the Ion Chef (Life Technologies). Samples were se-
quenced on the Ion S5 System (Life Technologies). Base calling was
performed on the Ion S5 (Life Technologies) with default parameters.
Subsequent steps included quality filtering and trimming using
bbduk version 37.25 (https://jgi.doe.gov/data-and-tools/bbtools/)
(k= 23 mink=11 ktrim= r hdist= 1 minlength= 50 qtrim= rl
trimq=20 ftl= 10 ftr= 600 maq=20 tpe tbo). Trimmed reads were
mapped to the KSHV genome (NC_009333) using CLC Version 11.0.1
(Qiagen Inc.). Variants were detected using the CLC basic variant de-
tection tool. Only variants that were non-synonymous, minimum
average quality score> 19, minimum frequency>90%, minimum
coverage> 40 and forward and reverse balance> 0.05 are reported.
For whole viral genome assembly, reads were error corrected and
normalized using BBmap (https://jgi.doe.gov/data-and-tools/bbtools/
). Next, sequences were aligned to NC_009333 and modified with an-
notation SOURCE = "NotCoveredByUNCAmpliSeq" to indicate regions
of the genome that were not included in the UNC-designed KSHV
AmplISeq PCR array using Geneious Prime® 2019.1 (Biomatters Ltd ).
Multiple best matches were mapped randomly, and a consensus was
built based on majority calls at a minimum read coverage of N = 5.
Thereafter the consensus was inspected and poly-nucleotide runs cor-
rected to restore full-length orfs. In an additional step, the error-cor-
rected reads were remapped against these consensus sequences and the
Fig. 1. Clinical manifestation of KICS
(A) PET-CT scans demonstrated hypermetabolic lymph nodes in chest, and the
(B) CT images taken in the same visit demonstrated presence of pulmonary KS.
Histopathology of transbrochial
biopsies showed (C) cancerous arrangement by H&E staining and (D) positive
histochemistry for LANA. (E) Timelines of each sample collection and tocili-
zumab treatment.
neutralizing antibodies at the University of North Carolina at Chapel 
Hill. Clinical and laboratory conditions of the KICS patient are com-
pared with a group of eleven KS and HIV-infected patients and six non-
KS and HIV-infected patients. The comparison further elucidates the 
pathogenesis of KICS and suggests IL-10 as a new biomarker for disease 
progression. Using genome-wide overlapping PCR (AmpliSeq), we ob-
tained the complete KSHV genome sequence from different time points 
of the disease. These represent one of the few KSHV sequences from 
circulating genomes, rather than tumor-associated, and potentially 
defective, KSHV genomes.
final consensuses were obtained. Gaps were repaired from the target to
restore open reading frames (annotated). In-frame Indels and SNV were
maintained. Six regions of the KSHV genome were not covered by
AmpliSeq primers: 24,213–25,057 (845 bp), 113949–114,092 (144 bp),
117,733–118,873 (1141 bp), 120,140–120,301 (162bp),
124,968–126,099 (1,132bp), and 137,588–137,917 (330 bp). Here, the
sequence from GQ994935 was inserted. The sequences are available in
GenBank (MK733606: UNC_KICS009, MK733608: UNC_KICS010,
MK733609: UNC_BAC16, MK733607: UNC_BC1). Coverage analysis
was conducted in R v3.6.0. Raw counts at each position were normal-
ized by applying a cube-root transformation, followed by log10 trans-
formation after (+1) was added to positions were counts where 0. Next,
the data were median-centered and a rolling window was applied to
calculate the median across 99 bp with an overlap of 33 bp. The code
and data are available at https://bitbucket.org/dittmerlab/kics2018/
src/master/.
Phylogenetic analysis. To compare our KSHV isolate to existing
whole genome data, the following sequences were used: NC009333,
LC200589, LC200588, LC200587, LC200586, AP017458, U93872,
KT271468, KT271467, KT271466, KT271465, KT271464, KT271463,
KT271462, KT271461, KT271460, KT271459, KT271458, KT271457,
KT271456, KT271455, KT271454, KT271453, GQ994935, KF588566,
JQ619843, JX228174, HQ404500 and AF148805. KICS patient se-
quences are indicated as consensus09 and consensus10. Full-length
consensus by majority vote genomic sequences, obtained after single
pass mapping of trimmed, error-corrected reads were used to generate a
multiple alignment using MAFFT (Katoh and Standley, 2013) with de-
fault options. The tree was generated using Geneious Prime® 2019.1
(https://www.geneious.com/) based on Jukes-Canter Distance and a
neighbor-joining algorithm with no outgroup. A consensus was gener-
ated by bootstrapping (n= 100). K1 sequence protein alignment was
based on 440 sequences in GenBank and also generated MAFFT with
BLOSUM62 matrix and visualized the same way.
Statistics. Results are reported as mean ± SD. All cellular
Fig. 2. Systemic viral and cytokine levels in the KICS
patient in comparison to KS and non-KS cases
A=Before KICS was established, patient was only
diagnosed with KS, B=After KICS diagnosis,
C=day 30, D= day 36. (A) KSHV DNA and (B) HIV
RNA levels in plasma from KICS patient at different
timepoints A, B, C and D and KS (n= 11) and non-KS
patients (n= 6). (C) IL-6, (D) IL-10 and (E) IL-8 on
patient plasma, measure by ELISA. For KICS, data
represents the mean ± SD of n= 3 independent
experiments of each plasma sample. For KS and non-
KS, each data point represents the mean of n=3
independent measurements, the mean ± SD was
calculated of the entire group (KS n= 11 and non-KS
n= 6). Principal component analysis of the 34-cy-
tokine measured by Luminex that characterizes (F)
the mayor drivers and (G) compares KICS and KS.
experiments were repeated in at least three complete biological re-
plicates. Unpaired 2-tailed t-test with Welch correction (not assuming
equal variance) was used to compare groups.
Study approval. Studies were approval by internal review board




The patient was a 45-year old male with HIV, who had initiated
treatment with an integrase inhibitor-based antiretroviral regimen
when he presented with dyspnea, fevers and violaceous skin lesions.
Skin biopsy confirmed KS. He was admitted one month later with dis-
ease progression. At that time, a computed tomography scan of the
chest demonstrated lung lesions thought to be pulmonary KS. The pa-
tient had recurrent episodes of fever and pancytopenia. As repeated
infectious evaluations were negative, these signs were thought to be
secondary to KS-IRIS. After initiating treatment with doxorubicin, he
had clinical improvement. Eight months later, his KS progressed and
required a change in treatment to paclitaxel. The patient was read-
mitted with shortness of breath, fatigue, pancytopenia and fevers. He
underwent a bronchoscopy with transbronchial biopsies confirming
pulmonary KS (Fig. 1A and B). KS biopsy was positive for LANA stain
(Fig. 1C and D). He was believed to have KICS rather than KS-IRIS and
treated with tocilizumab, a humanized monoclonal antibody against
the interleukin-6 receptor (IL-6R) that is approved for classic CD, with
good initial response. However, his health continued to decline despite
Fig. 3. A substantial fraction of circulating DNA is virion encapsulated
(A) Shown are relative levels of KSHV DNA, on a log 10 scale, as detected by
real-time QPCR on the vertical axis for samples with or without DNAse treat-
ment (horizontal axis). The colors indicate the different samples. For each
sample multiple replicates are shown. DNAse treatment was significant to
p≤ 0.001 by two-way ANOVA (n=25). The patient samples were: A=Before
KICS was established, patient was only diagnosed with KS (blue), B=After
KICS diagnosis (green), C=day 30 (purple), D= not available.
BCBL1= induced supernatant from BCBL1TREX (red). (B) Violin plot. Shown
on the vertical axis are raw Cp values for spiked in, naked control DNA either
DNAse or mock treated.
the addition of humanized monoclonal antibody against CD20 + B cells 
(rituximab) to his treatment regimen.
Blood samples from four different time points were available for 
analysis (Fig. 1E): (A) Day 0, patient was diagnosed with KS, (B) day 23, 
patient was diagnosed with KICS and had received first dose of tocili-
zumab 23 days earlier, (C) day 30, 1 h after patient received a second 
dose of tocilizumab and (D) day 36, i.e. six days after patient was 
treated with two doses of tocilizumab. The laboratory data of the KICS 
patient were compared to twelve KS/HIV-positive and six non-KS/HIV-
positive lymphoma patients. All patients were male ranging from 28 to 
59 years. The non-KS group included two cases with B-cell lymphoma, 
two diffuse large B-cell lymphoma, and two Hodgkin's lymphomas.
3.2. KICS patient had high levels of KSHV, but not HIV
At diagnosis (time point A), the patient had a KSHV viral load (total 
DNA) of 2.4 × 106 copies/mL, which decreased to 6.7 × 105 copies/mL 
at the end of study (time point D). The intermediate time points failed 
PCR extraction control and could not be analyzed. The KS group and 
non-KS group had an average of 280 copies/mL and 40 copies/mL of 
KSHV plasma DNA respectively, i.e. about a 3 10log lower than the 
lowest KICS value (Fig. 2A). Approximately half of the DNA signal was 
protected from DNAse I digestion (Fig. 3A) at time point A. No clinical 
material was left to conduct the same experiment for the other time 
points. In comparison greater than 80% of the DNA signal obtained 
from induced BCBL T-REx cells was DNAse sensitive. Exogenously 
added DNA served as control for DNAse activity and absence of DNAse 
inhibitors in serum (Fig. 3B). The KICS patient had an undetectable HIV 
viral load at all timepoints, while HIV viral load across the KS group 
ranged from undetectable to 5.2 × 103 copies/mL and across the non-
KS group from undetectable to 5.0 × 104 copies per mL (Fig. 2B). Thus, 
this case uncouples high-level KSHV replication from high-level HIV 
replication.
3.3. KICS could be differentiated from KS by its cytokine profile
To test the hypothesis that cytokine levels correlate with KICS and 
can be used to follow treatment, we measured (i) human IL-6, IL-10 and 
IL-8 by ELISA and (ii) a panel of 34 cytokines by Luminex in the KICS 
patient at timepoints A, B, C, and D, as well as in the KS positive 
(n = 11), and KS-negative (n = 6) cancer patients with HIV. 
Historically, high levels of IL-6 are associated with KICS; however, this 
patient did not exhibit elevated levels of IL-6 at time of KICS diagnosis 
(time point A (KS) undetectable, time point B (KICS diagnosios). 22 pg/
mL). IL-6 reactivity in ELISA increased 10-fold upon treatment with 
tocilizumab: to 324 pg/mL at 23 days after dose 1 (time point C), and 
222 pg/mL at 6 days after dose 2 (time point D) (Fig. 2C). IL-10 in-
creased 3-fold after the patient was clinically diagnosed with KICS to 
331 pg/mL (time point B), compared to KS (130 pg/mL (time point A), 
remained level after a single dose of tocilizumab (time point C) fol-
lowed by a drastic decrease at day 6 after the second tocilizumab 
treatment (time point D) (Fig. 2D). The KICS patient did not show 
substantial IL-8 levels at any of the timepoints (Fig. 2E). None of the 
patients in the KS or non-KS groups presented with elevated values of 
any of the three cytokines, confirming IL-6 and IL-10 as closely asso-
ciated with KICS.
Luminex-based multiplex analysis was used to study a broader range 
of cytokines. Principal component analysis identified IL-6 and IL-10 as 
the main cytokines driving the difference between KS and KICS on the 
one hand and between the different stages of KICS (PC1). TNF and IL-9, 
and pro-inflammatory cytokines were the main drivers of PC2 (Fig. 2F), 
which represents the difference between KS and non-KS. Together, PC1 
and PC2 explained 69.2% of the variation in the data. It was possible to 
differentiate KICS from KS on the basis of cytokine profiling and 
monitor disease progression (Fig. 2G, different shapes indicate the 
different time points). This confirms IL-6 as a diagnostic marker for
KICS and suggests that measuring IL-10 in addition may improve dis-
ease monitoring and differential diagnosis.
3.4. KSHV genomes in KICS
We used PCR-based enrichment (AmpliSeq) and Ion Torrent chem-
istry to determine the complete genome sequence of KSHV circulating
in this patient (submitted to GenBank). High-confidence whole gen-
omes were obtained for timepoints A and B, where KSHV viral loads
were high (≥105 copies/ml). 1,381,470 raw reads aligned to KSHV for
time point A yielding a mean coverage of 96.5 ± 36.9-fold
(Q20= 94.1%) covering 94.8% of the reference sequence with 91%
identical sites. 3,769,841 raw reads aligned to KSHV for time point B
yielding a mean coverage of 99.1 ± 35.4-fold (Q20=94%) covering
95.7% of the reference sequence with 90.8% identical sites. Time point
C did not have enough reads to cover the entire genome despite re-
peated attempts. Only 59.2% of the reference sequence was covered to
38.8 ± 46.9-fold coverage (Q20= 95.2%). Of that 91.7% were iden-
tical to the reference sequence. We also sequenced the KSHV out of
PBMC from these same time points. Time point D was virus negative.
This mapping used the KSHV reference sequence NC_009333 (Fig. 4A).
As positive control KSHV BAC16 and KSHV from BC1 cells were re-
sequenced. Six regions (see methods) were not covered by this Am-
pliSeq array. Every region contained in the array yielded mappable
reads, suggesting that no large-scale deletions or rearrangements had
occurred.
Independent of the whole genome assembly all reads were used for
single nucleotide variant (SNV) calling using high-confidence para-
meters as established for human SNV typing (Table 1). No InDels or
SNV were identified that were present in sample A and absent in sample
B. A number of SNV, relative to the consensus sequence were
consistently observed at both time points. At time point C, sequence
coverage was fragmented. Hence, a number of A/B-specific SNV could
not be confirmed. Notably, a series of three SNV in ORF24 were ob-
served only at time point C, but not at time points A and B. The majority
of non-synonymous SNV were shared with viral sequences obtained
from sequencing PBMC. Whether any of the sequence differences have
functional consequences remains to be explored. Based on a comparison
of 29 full length KSHV genome sequences, this isolate aligned to the
Western-European AIDS- PEL- and KS-derived sequences. More speci-
fically, both sequences aligned with clade A, shown in blue (Fig. 4B). It
suggests that the current KSHV reference sequence represents a com-
plete viral genome. In sum, this KICS case represented a rare and much
needed scientific opportunity to obtain complete KSHV genome in-
formation, pertaining to viral strains of demonstrated in vivo replication
potential and human infectivity.
4. Discussion
KICS represents the most aggressive and fatal outcome of KSHV
infection. KICS is convincingly associated with systemic high-level
KSHV replication and a cytokine storm dominated by IL-6 and IL-10
(Polizzotto et al., 2016; Uldrick et al., 2010). It is likely that these cy-
tokines are the mechanistic drivers of the clinical disease phenotype,
and they may constitute a target to ameliorate symptoms. Due to the
similarities between KICS and KSHV-MCD, treatments with efficacy in
KSHV-MCD may also have efficacy in KICS, although the accelerated
clinical course of KICS typically requires more aggressive interventions.
Further studies are needed to understand the biology of KICS and to
differentiate KICS from KSHV-MCD or KS-IRIS.
This particular KICS patient did not present elevated levels of IL-6.
Instead, IL-10 stood out as the clinical measurement that in addition to
Fig. 4. NextGen-sequencing analysis of KICS patient at different timepoints
(A) Distribution of reads that align to KSHV (NC009333) genome. Timepoint A in red (before KICS was established) and timepoint B in grey (after KICS was
diagnosed). Phylogenetic trees demonstrating alignment of generated consensus sequences for KSHV isolated from patient plasma, in comparison to (B) established
KSHV K1 clades and (C) previously reported KSHV sequences (A= 09 consensus and B=10 consensus, highlighted in red).
KSHV DNA copy number lead to the diagnosis of KICS. KSHV DNA copy
number decreased after treatment. Treatment also reduced IL-10 levels,
whereas IL-6 increased after tocilizumab was administered. Thus IL-10,
rather than IL-6 served as a better biomarker to follow disease pro-
gression after tocilizumab treatment of KICS. Because tocilizumab is an
IL-6 receptor inhibitor (reviewed in (Nishimoto and Kishimoto, 2004)),
it may have interfered with the IL-6 ELISA. Alternatively, IL-6, even
though present at high levels, may have had no biological activity on
IL6 receptor signaling due to the presence of tocilizumab. The re-
lationship between huIL6 and sIL6-R is quite complex. For instance,
native sIL6R serves to extend the half-life of IL6 in solution and en-
hances binding. Furthermore, soluble gp130 also exists at measurable
concentrations in blood. It is not entirely clear how adding anti-IL-6R
antibodies changes this equilibrium with regard to biology or diag-
nostic assay performance. Whether tocilizumab also affected viral IL6
signaling and what the viral IL6 levels were in this case is unknown due
to the low volume of sample and lack of reagents. Further studies to
evaluate the use of IL-10 as a biomarker for KICS seem warranted.
We successfully sequenced a KSHV genome from patient plasma,
rather than tumor tissue. Thus, this study contributes to the community
collection of whole genome KSHV sequences, which is still the most
limited among all herpesviruses (Brulois et al., 2012; Olp et al., 2015;
Russo et al., 1996; Sallah et al., 2018; Tamburro et al., 2012; Yakushko
et al., 2011). The sequencing data support the completeness of the
current KSHV reference sequence. Pre-NGS enrichment represented an
efficient method to sequence KSHV in the background of contaminating
human DNA and allowed full-length sequencing from KSHV from
PBMC. It did little, however, to overcome the dependence on high viral
genome copy number (105 copies/sample) in serum. Lower KSHV input
copy numbers yielded only partial genomes and are likely to suffer from
PCR bias. We were unable to design capture primers to the repeat re-
gions of the KSHV genome. Hence, the number of and sequence of re-
peats reported reflects the current reference genome and is likely an
underestimation of the true number of repeats (Lagunoff and Ganem,





168 CA TT 22 gln leu A, B, C A, B, C K1 Signaling
181 A C 26 asn thr A, B, C A, B, C
183 C T 27 leu phe A, B, C A, B, C
570 G A 155 ala thr .,., . A, B, C
609 C A 169 leu ile A, B, ND A, B, C
619 C G 172 ser trp A, B, ND A, B, C
699-761 199-219 (5)
2414 G T 435 ala ser A, B, C A, B,. ORF4 complement binding
3263 G C 29 val leu A, B, ND A, B, C ORF6 ssDNA binding
4364 G A 396 val met A, B, C A, B, C
5663 G C 829 asp his .,., . A, B, C
5844 T C 889 val ala ., B, ND A, B,.
6831 A G 80 thr ala A, B, C A, B,. ORF7 unknown
6901 T C 103 ile thr A, B, ND A, B, C
8517 A G 642 lys glu A, B, C A, B, C
14322 C G 998 ile met A,., ND A, B, C ORF9 DNA polymerase
15084 G T 200 met ile A, B, ND A, B,. ORF10 unknown
15093 A C 203 glu asp A, B, ND A, B, C
15116 C A 211 pro gln A, B, ND .,., .
15164 A G 227 tyr cys A, B, ND A, B, C
15078 C T 232 his tyr .,., . A, B, C
15214 A G 244 ile val A, B, ND A, B, C
15408 C T 308 glu asp .,., . A, B, C
15497 C T 338 thr ile .,., . A, B,.
15662 A G 393 his arg A, B, C A, B,.
15906 A C 51 asn his A, B, C A, B, C ORF11 unknown
17268 T C 192 asn asp A, B, C .,., . K2 DHFR
17817 T G 9 ile leu A, B, C A, B, C
17838 G A 2 arg cys A, B, C A, B, C
18647 A G 299 leu pro A, B, ND A, B,. K3
32659 A G 46 lys arg A, B, C A, B, C unknown
33960 G A 328 ala val A, B, C A, B, C ORF19 unknown
35959 G T 160 gly cys A, B, ND A, B, C ORF21 TK
41515 T A 455 asn leu .,., C .,., . ORF24 unknown
41518 T A 454 asn leu .,., C .,., .
41521 – A 453 fs fs .,., C .,., .
61287 C T 294 thr ile A, B, C .,., C ORF40 helicase-primase
99622 G A 227 pro ser A, B, C .,., . ORF61 assembly
131763 T C 943 ile val A,., ND .,., . orf75 FGARAT Homolog
135059 A G 412 leu pro A, B, ND A, B,. K15 Signaling
135882 T G 221 ser arg ., B, ND A, B, C
(1) Based on sequence GenBank ID: NC_009333.
(2) Based on original assignment by Russo et al. (1996) these refer to enzymatic functions that are conserved across herpesviruses and implicated in virus replication.
Function is inferred from sequence similarity across multiple homologous herpesviruses, not necessarily experiments. Conversely, many of the genes labeled “un-
known” function have shown specific activities in selective bioassays.
(3) Time point at which SNV was detected with high confidence in DNA isolated from plasma: A, B, C. The symbol “.” indicates the absence of the SNV at that time
point; “ND” indicates that no reliable sequence information was available at that time-point.
(4) Time point at which SNV was detected with high confidence in DNA isolated from PBMC: A′, B′, C.’ The symbol “.” indicates the absence of the SNV at that time
point; “ND” indicates that no reliable sequence information was available at that time-point.
(5) The complex repeat region in K1 was not resolved in virus isolated from plasma.
Table 1
Summary of non-synonymous mutations.
experiments, analyzed data and contributed to the final version of the
manuscript. All authors approved the final manuscript.
Summary of mutations
(1) Based on sequence GenBank ID: NC_009333
(2) Based on original assignment by Russo et al. (1996)
(3) Time point at which SNV was detected with high confidence: A, B,
C. The symbol “.” indicates the absence of the SNV at that time
point; “ND” indicates that no reliable sequence information was
available at that time-point.
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1997).
It is conceivable that a specific mutation in the KSHV genome is 
associated with a high replicative phenotype during KICS (Ray et al., 
2012). We were not able to identify a significant SNV that differed from 
consensus A (before KICS was diagnosed) and consensus B (after KICS 
was officially diagnosed). A limitation was unequal genome coverage, 
as a higher mean genome coverage was obtained from PBMC due to 
advances in sequencing technology. As expected, the virus had low 
genetic variation over time and when compared to the reference 
genome. The exception being the variable regions in K1. Whether any 
of the non-synonymous SNV could have impacted viral replication is 
the subject of future studies. As this study sequenced total DNA rather 
than encapsulated, virion DNA, it most likely reflects a mixture of virion 
DNA and fragments of viral DNA, released by dying cells. In support of 
this assessment, some SNV were seen in sequences obtain from serum 
DNA at multiple time points, but not in the corresponding DNA ob-
tained from PBMC and vice versa, e.g. K1 at aa 155 or orf10 at aa 211.
Alternatively, the patient's genome could harbor SNV that predis-
posed him to KSHV infection or resulted in a suboptimal response to 
viral reactivation. Here, the interpretive value of a single case study is 
necessarily limited. Whole Exome sequencing yielded 1979 previously 
reported homozygous SNV, of which 338 were annotated in ClinVar. 
We do not know the significance of any of them, but these included 
biologically plausible candidates SNV in genes such as IL-4R, IL-13, 
TRL1 or TAB2.
The patient presented in this study was HIV seropositive, but at the 
time had no detectable HIV viral load. This was unexpected if one 
considers KSHV-associated malignancies in the context of late-state 
AIDS, as during the 1990 epidemic in US and European men who have 
sex with men Centers for Disease (1981); however, KS has since become 
appreciated as a much more varied disease entity. Particularly in KSHV-
endemic regions, KS is independent of HIV viral load and CD4 counts 
(Hosseinipour et al., 2014). In the same setting, IL6 and IL10 are often 
elevated in pediatric KS with lymph node involvement and KSHV-MCD 
is seen more frequently than previously assumed, reinforcing the con-
nection between KSHV replication and KSHV-induced pathology in the 
lymphoid compartment. In summary, clinical complications and ma-
lignancies associated with KSHV infection have become more varied. A 
better understanding of viral pathogenesis is needed to validate clini-
cally relevant biomarkers and discover novel interventions.
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